Cadent Therapeutics rakes in $40 mln Series B
Cadent Therapeutics, a developer of therapies focused on movement and cognitive disorders, has raised $40 million in Series B financing. Cowen Healthcare Investments and Atlas Venture led the round with participation from Qiming Venture Partners, Access Industries, Clal Biotechnology Industries and Novartis Institutes for Biomedical Research. In addition, the company has appointed Dr. Bob Dagher as chief medical officer.
15 November 2018•1 min read
